Cyclacel Pharmaceuticals update Phase 2 survival data of sapacitabine for MDS

theflyonthewall.com

Cyclacel Pharmaceuticals announced updated median overall survival data from an ongoing, multicenter, Phase 2 randomized trial of oral sapacitabine capsules, the company's lead product candidate, in older patients with intermediate-2 or high-risk myelodysplastic syndromes, or MDS, after treatment failure of front-line hypomethylating agents, such as azacitidine and/or decitabine. Median overall survival to date for all 63 patients treated is approximately 9 months. Median overall survival for each of the three randomization schedules is approximately 10 months for Arm G, 10 months for Arm H and 8 months for Arm I. The 30-day mortality for all patients is 5%.

View Comments (0)